Burrell Terry-Ann has filed 37 insider transactions across 2 companies since January 2023.
Most recent transaction: a grant/award of 1843 shares of RECURSION PHARMACEUTICALS, INC. ($RXRX) on July 01, 2024.
Activity breakdown: 0 open-market purchases and 13 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| July 1, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | A | Class A Common Stock | 1843 | $0.00 | 71,254.0000 | 0 | 2.66% | 0.00% |
| June 3, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | A | Class A Common Stock | 13097 | $0.00 | 69,411.0000 | 0 | 23.26% | 0.00% |
| June 3, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | A | Stock Option (Right to Buy) | 26193 | $0.00 | 26,193.0000 | 0 | 9999.99% | 0.00% |
| April 26, 2024 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | A | Common Stock | 12500 | $0.00 | 82,637.0000 | 77,151,771 | 17.82% | 0.02% |
| April 26, 2024 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | A | Stock Option (Right to Buy) | 25000 | $0.00 | 25,000.0000 | 77,151,771 | 9999.99% | 0.03% |
| April 1, 2024 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | S | Common Stock | 5446 | $32.12 | 70,137.0000 | 77,151,771 | 7.21% | 0.01% |
| April 1, 2024 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | A | Class A Common Stock | 1467 | $0.00 | 56,314.0000 | 0 | 2.67% | 0.00% |
| March 31, 2024 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | A | Common Stock | 27500 | $0.00 | 75,583.0000 | 77,151,771 | 57.19% | 0.04% |
| Jan. 31, 2024 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | A | Stock Option (Right to Buy) | 55000 | $24.40 | 55,000.0000 | 77,151,771 | 9999.99% | 0.07% |
| July 12, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | S | Class A Common Stock | 24302 | $11.25 | 147,545.0000 | 0 | 14.14% | 0.00% |
| July 13, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | S | Class A Common Stock | 8275 | $12.59 | 54,847.0000 | 0 | 13.11% | 0.00% |
| July 12, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | S | Class A Common Stock | 3157 | $14.08 | 63,122.0000 | 0 | 4.76% | 0.00% |
| July 12, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | S | Class A Common Stock | 3195 | $13.18 | 66,279.0000 | 0 | 4.60% | 0.00% |
| July 12, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | S | Class A Common Stock | 78071 | $12.15 | 69,474.0000 | 0 | 52.91% | 0.00% |
| June 16, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | A | Class A Common Stock | 12612 | $0.00 | 171,847.0000 | 0 | 7.92% | 0.00% |
| June 16, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | A | Stock Option (Right to Buy) | 25224 | $0.00 | 478,702.0000 | 0 | 5.56% | 0.00% |
| Jan. 31, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 70,015,305 | 9999.99% | 0.06% |
| April 4, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | S | Common Stock | 2186 | $29.09 | 47,117.0000 | 70,015,305 | 4.43% | 0.00% |
| April 3, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | S | Common Stock | 2454 | $30.31 | 49,303.0000 | 70,015,305 | 4.74% | 0.00% |
| Jan. 31, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | A | Stock Option (Right to Buy) | 20000 | $0.00 | 20,000.0000 | 70,015,305 | 9999.99% | 0.03% |
| March 31, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | A | Common Stock | 20000 | $0.00 | 51,277.0000 | 70,015,305 | 63.94% | 0.03% |
| Jan. 26, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | S | Common Stock | 1102 | $45.16 | 31,277.0000 | 70,015,305 | 3.40% | 0.00% |
| Jan. 27, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | M | Common Stock | 36152 | $13.68 | 67,429.0000 | 70,015,305 | 115.59% | 0.05% |
| Jan. 27, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | M | Stock Option (Right to Buy) | 36152 | $0.00 | 185,565.0000 | 70,015,305 | 16.31% | 0.05% |
| Jan. 26, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | M | Stock Option (Right to Buy) | 1102 | $0.00 | 221,717.0000 | 70,015,305 | 0.49% | 0.00% |
| Jan. 27, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | S | Common Stock | 36152 | $45.08 | 31,277.0000 | 70,015,305 | 53.61% | 0.05% |
| Jan. 26, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | M | Common Stock | 1102 | $13.68 | 32,379.0000 | 70,015,305 | 3.52% | 0.00% |
| Jan. 24, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | S | Common Stock | 14810 | $45.01 | 31,277.0000 | 70,015,305 | 32.13% | 0.02% |
| Jan. 24, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | M | Stock Option (Right to Buy) | 14810 | $0.00 | 222,819.0000 | 70,015,305 | 6.23% | 0.02% |
| Jan. 24, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | M | Common Stock | 14810 | $13.68 | 46,087.0000 | 70,015,305 | 47.35% | 0.02% |
| Jan. 23, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | S | Common Stock | 5426 | $45.02 | 31,277.0000 | 70,015,305 | 14.78% | 0.01% |
| Jan. 23, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | M | Common Stock | 5426 | $13.68 | 36,703.0000 | 70,015,305 | 17.35% | 0.01% |
| Jan. 23, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | M | Stock Option (Right to Buy) | 5426 | $0.00 | 237,629.0000 | 70,015,305 | 2.23% | 0.01% |
| Jan. 18, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | S | Common Stock | 47195 | $45.14 | 31,277.0000 | 70,015,305 | 60.14% | 0.07% |
| Jan. 18, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | M | Common Stock | 39886 | $13.68 | 78,472.0000 | 70,015,305 | 103.37% | 0.06% |
| Jan. 18, 2023 | Beam Therapeutics Inc. | $BEAM | Burrell Terry-Ann | Chief Financial Officer | M | Stock Option (Right to Buy) | 39886 | $0.00 | 243,055.0000 | 70,015,305 | 14.10% | 0.06% |
| Jan. 3, 2023 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Burrell Terry-Ann | Director | A | Class A Common Stock | 1821 | $0.00 | 159,235.0000 | 0 | 1.16% | 0.00% |